Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:VRTX News 13 December 2025 - 22 January 2026

Vertex stock jumps 4% as earnings date nears — what traders watch next for VRTX

Vertex stock jumps 4% as earnings date nears — what traders watch next for VRTX

New York, Jan 22, 2026, 05:11 EST — Premarket Vertex Pharmaceuticals (VRTX) shares jumped 4.31%, closing Wednesday at $461.14 and marking their third straight session of gains. Trading volume climbed past the stock’s 50-day average. VRTX outperformed peers like AbbVie, Krystal Biotech, and Arcturus Therapeutics, while the S&P 500 and Dow each gained over 1%. (MarketWatch) Vertex is now under the spotlight ahead of its next major event: the company will release its fourth-quarter and full-year 2025 results after the U.S. market closes on Feb. 12, followed by a conference call and webcast at 4:30 p.m. ET. The company has
22 January 2026
·····
CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

CRISPR Therapeutics stock slides after CFO share-sale filing; JPM conference next

New York, Jan 9, 2026, 15:11 EST — Regular session CRISPR Therapeutics AG shares slid on Friday, bucking a firmer broader market, after a regulatory filing flagged a chief financial officer’s share sale under a pre-arranged trading plan. (Reuters) The company’s CFO, Raju Prasad, exercised stock options for 29,700 common shares and sold 29,700 shares the same day at prices around $60, a Form 4 filed on Jan. 8 showed. The filing indicated the sales were made under a Rule 10b5-1 plan, a preset trading instruction meant to limit allegations of trading on inside information. (SEC) The timing matters because
9 January 2026
········
CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

NEW YORK, January 1, 2026, 18:59 ET — Market closed Shares of CRISPR Therapeutics AG ended the last trading session of 2025 down 1.4% at $52.44. U.S. stock markets were closed on Thursday for New Year’s Day, according to the NYSE holiday calendar. StockAnalysis+1 The pullback matters because CRISPR heads into 2026 with its first commercial product still early in launch and with investors seeking clearer signs of demand. The stock has tended to react sharply to shifts in sentiment around gene-editing drugmakers. Traders are also looking ahead to the next set of checkpoints: read-throughs from partner Vertex Pharmaceuticals, which
2 January 2026
········
Vertex Pharmaceuticals (VRTX) Stock Week Ahead: Holiday-Shortened Trading, New Gene-Therapy Data, and Fresh Analyst Targets (Dec. 22–26, 2025)

Vertex Pharmaceuticals (VRTX) Stock Week Ahead: Holiday-Shortened Trading, New Gene-Therapy Data, and Fresh Analyst Targets (Dec. 22–26, 2025)

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) heads into the week of December 22–26, 2025 with a familiar setup for biotech investors: a cash-rich market leader in cystic fibrosis (CF), a pipeline that could meaningfully diversify revenue over the next 12–24 months, and a stock that can move quickly on headlines—even when broader markets are quiet. The difference this time is the calendar. U.S. equities trading will be compressed by Christmas, with an early close on Wednesday, Dec. 24 (1:00 p.m. ET) and markets closed Thursday, Dec. 25. That tends to thin liquidity and can magnify price swings—up or down—on even modest
22 December 2025
····
Vertex Pharmaceuticals (VRTX) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025: Casgevy Pediatric Data, Kidney Pipeline Momentum, and Journavx Launch Watch

Vertex Pharmaceuticals (VRTX) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025: Casgevy Pediatric Data, Kidney Pipeline Momentum, and Journavx Launch Watch

December 20, 2025 — Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) heads into the year’s final stretch with investors focused on a familiar question: can the biotech’s next wave of launches and late-stage programs begin to meaningfully diversify a cystic fibrosis (CF) business that has dominated its revenue for more than a decade? VRTX shares most recently closed at $456.20 on Friday, Dec. 19, up 1.97% in that session. StockAnalysis Below is the current news, forecasts, and market analysis shaping Vertex stock as of Dec. 20, 2025, including the latest on Casgevy’s pediatric data, Journavx’s commercial ramp, and a kidney-disease pipeline that
21 December 2025
·····
Vertex Pharmaceuticals (VRTX) Stock After Hours on Dec. 19, 2025: Today’s News, Analyst Forecasts, and What to Know Before Monday’s Market Open

Vertex Pharmaceuticals (VRTX) Stock After Hours on Dec. 19, 2025: Today’s News, Analyst Forecasts, and What to Know Before Monday’s Market Open

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) finished Friday, December 19, 2025, on a strong note and then stayed relatively steady in after-hours trading—setting up a familiar “what happens next?” question for investors heading into the final full week before year-end. Below is a detailed rundown of what moved VRTX today, what the after-hours tape is saying, what analysts are forecasting right now, and the key catalysts to watch before the next U.S. market open (Monday, December 22, 2025). VRTX after the bell: where the stock closed and how it traded after hours VRTX rose 1.97% in the regular session to close
20 December 2025
·····
Vertex Pharmaceuticals (VRTX) Stock: What to Know Before the Market Opens on Dec. 15, 2025

Vertex Pharmaceuticals (VRTX) Stock: What to Know Before the Market Opens on Dec. 15, 2025

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) heads into the Monday, December 15, 2025 U.S. market open with investors weighing a familiar mix: a dominant cystic fibrosis (CF) franchise that funds the story, and a fast-expanding pipeline that’s increasingly driving the debate about what Vertex should be worth next. The stock ended the last regular session (Friday, Dec. 12) at $452.04, up 1.37% on the day, extending a three-session winning streak and outperforming a down market. MarketWatch At the same time, shares remain about 13% below the 52-week high of $519.68 set in March, reflecting how much scrutiny remains on the pace
15 December 2025
·····
Vertex Pharmaceuticals (VRTX) Stock: This Week’s News, Analyst Forecasts, and the Week-Ahead Outlook (Updated Dec. 12, 2025)

Vertex Pharmaceuticals (VRTX) Stock: This Week’s News, Analyst Forecasts, and the Week-Ahead Outlook (Updated Dec. 12, 2025)

Updated: Dec. 12, 2025 (U.S. market close) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) finished Friday at $452.04, extending a late-week rebound after a choppy start to the week. The stock’s intraday range on Friday stretched from $442.94 to $455.99 on volume of about 1.62 million shares, as biotech investors weighed fresh pipeline headlines, Wall Street price-target moves, and a shifting macro backdrop following the Federal Reserve’s latest rate decision. MarketWatch+1 Below is a detailed, publication-ready breakdown of all notable VRTX news from the past several days, the latest analyst forecasts, and what could matter most for next week’s trading. VRTX stock
13 December 2025
·····

Stock Market Today

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop